250 related articles for article (PubMed ID: 35790913)
1. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
[TBL] [Abstract][Full Text] [Related]
2. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
3. The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
Rui YN; Xu Z; Chen Z; Zhang S
Autophagy; 2015; 11(5):812-32. PubMed ID: 25984893
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
5. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
7. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
8. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
[TBL] [Abstract][Full Text] [Related]
9. Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
Vieri M; Preisinger C; Schemionek M; Salimi A; Patterson JB; Samali A; Brümmendorf TH; Appelmann I; Kharabi Masouleh B
Carcinogenesis; 2021 Feb; 42(2):272-284. PubMed ID: 32915195
[TBL] [Abstract][Full Text] [Related]
10. Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.
Yamashita Y; Morita S; Hosoi H; Kobata H; Kishimoto S; Ishibashi T; Mishima H; Kinoshita A; Backes BJ; Yoshiura KI; Papa FR; Sonoki T; Tamura S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878237
[TBL] [Abstract][Full Text] [Related]
11. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
14. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
15. The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
Chen H; Yang H; Pan L; Wang W; Liu X; Ren X; Liu Y; Liu W; Zhang Y; Jiang L; Li K; Zhang B; Wang LX
Biomed Pharmacother; 2016 Feb; 77():108-13. PubMed ID: 26796273
[TBL] [Abstract][Full Text] [Related]
16. Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors.
Xu G; Huang S; Peng J; Gao X; Li M; Yu S; Liu Z; Qie P; Wang Y; Yu S; Liu S; Wen H; Su L; Li P; Guang B; Dong R; Liu J; Yang T
Br J Pharmacol; 2021 Dec; 178(23):4741-4757. PubMed ID: 34378191
[TBL] [Abstract][Full Text] [Related]
17. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
Sun H; Lin DC; Guo X; Kharabi Masouleh B; Gery S; Cao Q; Alkan S; Ikezoe T; Akiba C; Paquette R; Chien W; Müller-Tidow C; Jing Y; Agelopoulos K; Müschen M; Koeffler HP
Oncotarget; 2016 Apr; 7(14):18736-49. PubMed ID: 26934650
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.
Davenport EL; Moore HE; Dunlop AS; Sharp SY; Workman P; Morgan GJ; Davies FE
Blood; 2007 Oct; 110(7):2641-9. PubMed ID: 17525289
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
